Recent advances in the search for novel 5-lipoxygenase inhibitors for the treatment of asthma.

Abstract

The products of 5-lipoxygenase are synthesized and released in the airway when an asthmatic reaction occurs. 5-lipoxygenase via arachidonic acid metabolism produces leukotrienes that mediate bronchoconstriction and inflammatory modifications essential in the pathophysiology of asthma. Until to now, only one approved 5-LO inhibitor, zileuton, can be found as a potential therapy for asthma. With the increasing number of indications for anti-leukotriene (anti-LT) drugs, the development of 5-LO inhibitor agents becomes increasingly important. The present MiniReview reports an update on 5-LO inhibitors currently under clinical investigation. In addition, the latest advances focused on the development of new 5-lipoxygenase inhibitors as asthma anti-inflammatory agents are also discussed.

• Authors: Ferdinando Bruno, Giuseppe Spaziano, Angela Liparulo, Fiorentina Roviezzo, Seyed Mohammed Nabavi, Antoni Sureda, Rosanna Filosa, Bruno D'Agostino
• Journal: European journal of medicinal chemistry (Eur J Med Chem) Vol. 153 Pg. 65-72 (Jun 10 2018) ISSN: 1768-3254 [Electronic] France
• PMID: 29133059 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2017. Published by Elsevier Masson SAS.

Chemical References

• Anti-Inflammatory Agents
• Leukotrienes
• Lipoxygenase Inhibitors
• Arachidonate 5-Lipoxygenase

Topics

• Animals
• Anti-Inflammatory Agents (chemistry, pharmacology, therapeutic use)
• Arachidonate 5-Lipoxygenase (immunology, metabolism)
• Asthma (drug therapy, immunology, metabolism)
• Clinical Trials as Topic
• Drug Discovery
• Humans
• Leukotrienes (immunology, metabolism)
• Lipoxygenase Inhibitors (chemistry, pharmacology, therapeutic use)